LJP 394 suppressor of double-strand DNA antibodies data

LJPC reported additional Phase II findings at the meeting of the American College of Rheumatology in Orlando, Fla. The agent gave improved indicators of kidney disease

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE